Plasma Levels of the MiR-193b/365a Cluster in Combination with Clinical Parameters Predict Response to Lactococcus Lactis-based Antigen-specific Combination Therapy

Presenting Author(s)

• GS

  Gabriele Sassi, n/a

  KU Leuven
  Leuven, Vlaams-Brabant, Belgium

Chair(s)

• JV

  Jo L. Viney, PhD

  Chief Scientific Officer
  Pandion Therapeutics
  Watertown, Massachusetts, United States